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Abstract
IMPORTANCE Inflammation is a key driver of malnutrition during illness and is often accompanied
by metabolic effects, including insulin resistance and reduction of appetite. However, it still remains
unclear if inflammation influences the response to nutritional support among patients with
disease-relatedmalnutrition.
OBJECTIVE To examine whether patients’ baseline inflammatory status is associated with the effect
of nutritional support on 30-daymortality.
DESIGN, SETTING, AND PARTICIPANTS This is a secondary analysis of the Effect of Early
Nutritional Support on Frailty, Functional Outcomes, and Recovery of MalnourishedMedical
Inpatients Trial (EFFORT), a randomized clinical trial conducted in 8 Swiss hospitals from April 2014
to February 2018. A total of 1950 participants who had C-reactive protein measurements at the time
of admission were included in this secondary analysis. Data analysis was conducted between June
and July 2019.
INTERVENTIONS Hospitalized patients at risk for malnutrition were randomly assigned to receive
protocol-guided individualized nutritional support to reach protein and energy goals (intervention
group) or standard hospital food (control group).
MAINOUTCOMES ANDMEASURES The primary end point was 30-daymortality. Based on
C-reactive protein levels at admission, patients were stratified into groups with low, moderate, or
high inflammation (<10mg/L, 10-100mg/L, and >100mg/L, respectively).
RESULTS A total of 1950 patients (median [interquartile range] age, 75 [65-83] years; 1025 [52.6%]
men) were included; 533 (27.3%) had low levels of inflammation, 894 (45.9%) hadmoderate levels
of inflammation, and 523 (26.8%) had high levels of inflammation. Comparedwith the control group,
patients receiving nutritional support showed a significant reduction in 30-daymortality, regardless
of C-reactive protein level (adjusted odds ratio, 0.61; 95% CI, 0.43-0.86; P = .005). In the subgroup
of patients with high inflammation, there was no beneficial effect of nutritional support (adjusted
odds ratio, 1.32; 95% CI, 0.70-2.50; P = .39), providing evidence that inflammation has a significant
modifying association (P for interaction = .005).
CONCLUSIONS ANDRELEVANCE Based on this secondary analysis of a multicenter randomized
trial, a patient’s admission inflammatory status was associated with their response to nutritional
support. If validated in future clinical trials, nutritional support may need to be individualized based
(continued)
Key Points
Question Does nutritional support have
a similar effect on 30-daymortality
among patients with high inflammation
compared with patients with low or
moderate inflammation?
Findings In this secondary analysis of a
Swiss multicenter trial, including 1950
patients at risk of malnutrition, patients
with high levels of inflammation based
on their levels of C-reactive protein at
admission were not associated with a
beneficial effect of nutritional support
on 30-daymortality compared with the
overall population, suggesting that
inflammation has a significant modifying
association.
Meaning Based on this secondary
analysis of a multicenter randomized
trial, patients’ inflammatory status at
admission was associated with their
response to nutritional support andmay
be considered when individualizing the
nutritional management of medical
inpatients.
+ Visual Abstract
+ Supplemental content
Author affiliations and article information are
listed at the end of this article.
Open Access. This is an open access article distributed under the terms of the CC-BY License.
JAMA Network Open. 2020;3(3):e200663. doi:10.1001/jamanetworkopen.2020.0663 (Reprinted) March 10, 2020 1/12
Downloaded From: https://jamanetwork.com/ on 07/01/2020
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.2
44
51
/a
rb
or
.1
17
85
 
| 
do
wn
lo
ad
ed
: 
31
.1
0.
20
20
Abstract (continued)
on a patient’s initial presentation andmarkers of inflammation. These results may also help to explain
some of the heterogeneity in treatment effects of nutrition seen in previous critical care trials.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02517476
JAMA Network Open. 2020;3(3):e200663. doi:10.1001/jamanetworkopen.2020.0663
Introduction
Disease-related malnutrition is a frequent condition among hospitalized medical inpatients, with a
prevalence of 20% to 50%.1-3 The 2019 Effect of Early Nutritional Support on Frailty, Functional
Outcomes, and Recovery of MalnourishedMedical Inpatients Trial (EFFORT)4 demonstrated that
starting individualized nutritional support early reduces complications andmortality amongmedical
inpatients at risk for malnutrition. Interestingly, there was little evidence in this trial for subgroup
effects regarding nutritional status and type of medical disease. Nevertheless, independent of
medical disease, patients’ inflammatory status could influence their response to nutritional support
for several reasons.
Inflammation has several metabolic effects, including an increase in insulin resistance and
reduction of appetite, leading to an inhibition of nutrition entering cells.5,6 In fact, independent of
underlying disease, inflammation is thought to be a key driver for disease-related anorexia, reduced
food intake, and muscle catabolism. This may also partly explain the inferior patient outcomes
associated with inflammation, which include longer hospital stays and increasedmortality.7,8 The
relevance of inflammation in the pathogenesis of malnutrition is also reflected in its classification by
the European Society of Clinical Nutrition and Metabolism (ESPEN). They recommend dividing
malnutrition into disease-relatedmalnutrition with and without inflammation.9 Disease-related
malnutrition with inflammation is defined as underlying diseases causing inflammation with a
consecutive lack of food intake or as uptake with a negative nutrient balance.10 Although several
mainly preclinical studies have evaluated the relevance of inflammation onmalnutrition, there is a
lack of clinical data investigating whether the inflammatory status of a patient influences treatment
response to nutritional support.
To close this gap, we conducted a secondary analysis of a prospective randomized clinical trial
that included consecutive patients with malnutrition at the time of hospital admission. We
investigated whether the inflammatory status of patients, as mirrored by their levels of C-reactive
protein (CRP) at admission, was associated with treatment response within the trial and whether
nutritional support was associated with CRP kinetics over time. Knowledge of such factors could
improve our physiopathological understanding of the role nutrition plays during acute illness and
may enable a more individualized nutritional approach to patients.
Methods
StudyDesign and Setting
This is a secondary analysis of EFFORT, a pragmatic, investigator-initiated, open-label, multicenter
trial that was undertaken in 8 Swiss hospitals from April 2014 to February 2018. Between June and
July 2019, we performed this secondary analysis. Reporting of the results follows the Consolidated
Standards of Reporting Trials (CONSORT) reporting guideline for randomized clinical trials.11 The Ethics
Committee of Northwestern Switzerland approved the study protocol, and all patients or their
authorized representatives providedwritten informed consent. Themain aimwas to assess the effects
of early nutritional support on patient outcomes in themedical inpatient setting. Rationale for the trial,
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design details, and eligibility features12 as well as themain results4 have been published previously.
The trial protocol is available in Supplement 1.
Patient Population andManagement
In EFFORT, consecutive patients at nutritional risk (ie, Nutritional Risk Screening [NRS] 2002 total
score3 points13) with an expected hospital stay of at least 5 days were enrolled if they were willing
to provide informed consent. Patients were excluded if theywere initially admitted to intensive care
units or surgical units; were unable to ingest oral nutrition; were already receiving nutritional support
before admission; had a terminal condition (ie, end-of-life situation); were hospitalized because of
anorexia nervosa, acute pancreatitis, acute liver failure, cystic fibrosis, or stem cell transplantation;
had undergone gastric bypass surgery; had contraindications for nutritional support; or were
previously included in the trial. While EFFORT included a total of 2028 patients, this secondary
analysis included 1950 patients (96.2%) whose CRP levels were measured at time of admission as
part of the clinical routine.
Upon admission, medical diagnosis according to International Statistical Classification of
Diseases and Related Health Problems, Tenth Revision (ICD-10) codes, sociodemographic and
anthropometric data, baseline muscle strength, and functional status (using the Barthel scale) were
assessed in all patients based on the trial protocol. Following discharge, masked study nurses
contacted patients after 30 and 180 days for a structured telephone interview. Prespecified health-
related outcomes were systematically assessed at these points.
Patient Groups and End Points
We allocated patients to 3 groups according to their inflammatory status at time of admission. Low
inflammation was defined as CRP levels less than 10 mg/L, moderate as 10 mg/L to 100 mg/L, and
high as greater than 100 mg/L (to convert CRP to nanomoles per liter, multiply by 9.524). These
cutoffs were predefined based on a clinical rationale and prior experience with CRP levels among
patients with various degrees of inflammation.14
Our main aimwas to investigate whether a patient’s inflammatory status was associated with
the effect of nutritional support on important outcomes. We compared different end points among
patients receiving protocol-guided personalized nutritional support (ie, the intervention group) with
those receiving standard hospital food (ie, the control group) within the predefined subgroups.
The primary end point was all-cause mortality after 30 days. Secondary end points were
180-daymortality, major complications, decline in functional status according to the Barthel scale at
30 and 180 days, and length of hospital stay. Adverse outcomeswere defined as all-causemortality,
admission to intensive care units, and nonelective hospital readmission. The Barthel scale measures
performance in activities of daily living and comprises 2 groups of items, 1 related to self-care (ie,
feeding, grooming, bathing, dressing, bowel and bladder care, and toilet use) and the other to
mobility (ie, ambulation, transfers, and stair climbing). We used the German version, which has
scores ranging from 100 to 0, with lower scores indicating more severe disability. We defined decline
as a reduction of 10% ormore on the Barthel scale from time of admission.
Statistical Analysis
Continuous variables were expressed as medians and interquartile ranges (IQRs), and frequencies
were expressed as percentages and counts. We calculated logistic regression analysis and report
odds ratios (ORs) and 95% CIs. We adjusted all analyses for predefined factors, including sex, age,
baseline nutritional risk (ie, NRS 2002 score), study center, Barthel scale at baseline, main diagnosis,
cardiovascular disease, renal disease, and cancer.We studied the effect of nutritional support overall
and in subgroups by comparing outcomes among patients receiving nutritional support with control
patients not receiving support. We included interaction terms in the statistical models to investigate
whether there was evidence for effect modification due to baseline inflammatory status of patients
(ie, low, moderate, or high inflammation). As a sensitivity analysis, we also included CRP as a
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continuous marker in themodel. Finally, we performed a subgroup analysis limiting data to patients
with a main diagnosis of infection to understand whether inflammation or infection was the main
driver of results.
All statistical analyses were performed using Stata version 15.1 (StataCorp). P < .05 was
considered statistically significant, and all tests were 2-tailed.
Results
Patient Population
From an initial population of 2028 EFFORT trial patients (Figure 1), we had available CRP levels for
1950 patients (96.2%), of whom 533 (27.3%) had low levels of inflammation (CRP levels <10mg/L),
894 (45.9%) hadmoderate levels of inflammation (CRP levels 10-100mg/L), and 523 (26.8%) had
high levels of inflammation (CRP levels >100 mg/L). Baseline characteristics for the overall
population and those stratified according to inflammation status are shown in Table 1. The median
(IQR) age of the population was 75 (65-83) years, and 1025 (52.6%) were men. All patients were at
nutritional risk, with 598 (30.7%), 751 (38.5%), 499 (25.6%), and 102 (5.2%) having NRS 2002
scores of 3, 4, 5 and at least 6 points, respectively. Themost commonmain diagnoses were infectious
disease (592 [30.4%]), cancer (360 [18.5%]), and cardiovascular disease (197 [10.1%]), with
significant differences among inflammation groups. For example, more patients with infectious
diseases were in the high inflammation group than in themoderate or low inflammation groups (314
[60.0%] vs 235 [26.3%] vs 43 [8.1%]; P < .001), andmore patients with cardiovascular diseasewere
in the low inflammation group than in the moderate or high inflammation groups (72 [13.5%] vs 114
[12.8%] vs 11 [2.1%]; P < .001). The eTable in Supplement 2 also shows patient baseline and mean
Figure 1. Flow of Patients Through the Trial
5015 Patients screened for trial inclusion 
3137 Eligible
1050 Randomized to intervention 1038 Randomized to control
1015 Included in main trial 1013 Included in main trial 
978 Included in final analysis 972 Included in final analysis 
2088 Randomized
1878 Excluded
145 Were surgical patients
719 Were already receiving nutritional therapy on admission
268 Were unable to ingest oral nutrition
158 Had a terminal condition
31 Were hospitalized because of anorexia nervosa
6 Had cystic fibrosis
161 Had acute pancreatitis
81 Had acute liver failure
11 Had stem‐cell transplantation
228 Had earlier inclusion in the trial 
27 Had malnutrition after gastric bypass operation
43 Had a contraindication against nutritional therapy
35 Withdrew consent
37 Had no CRP measurement
25 Withdrew consent
41 Had no CRP measurement
1049 Refused participation
CRP indicates C-reactive protein.
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nutritional intake data during the hospital stay according to randomization group and stratified
according to CRP group. Overall, baseline data were well balanced according to randomization
groups within CRP groups. There were significantly higher mean calorie and protein intakes among
patients in the intervention group compared with patients in the control group, regardless of CRP
level (eg, high inflammation group: mean [SD] protein intake, 54.6 [23.5] g/d vs 44.7 [19.5] g/d;
P < .001; mean [SD] calorie intake, 1432 [606] kcal/d vs 1138 [449] kcal/d; P < .001).
Table 1. Baseline Characteristics Overall and Stratified by Inflammation Level
Characteristic
No. (%)
P Value
Overall
(N = 1950)
CRP Levels <10 mg/L
(n = 533)
CRP Levels 10-100 mg/L
(n = 894)
CRP Levels >100 mg/L
(n = 523)
Age, median (IQR), y 75 (65-83) 74 (62-83) 76 (67-83) 74 (66-81) .03
Men 1025 (52.6) 250 (46.9) 490 (54.8) 285 (54.5) .009
BMI
Median (IQR) 24.0 (21.0-28.0) 23.0 (20.0-27.0) 24.0 (21.0-28.0) 25.0 (21.5-28.0) <.001
<18.5 173 (8.9) 72 (13.5) 67 (7.5) 34 (6.5)
<.00118.5-25 1017 (52.3) 288 (54.0) 473 (53.1) 256 (49.2)
>25 754 (38.8) 173 (32.5) 351 (39.4) 230 (44.2)
NRS 2002 score
3 598 (30.7) 198 (37.1) 294 (32.9) 106 (20.3)
<.001
4 751 (38.5) 211 (39.6) 328 (36.7) 212 (40.5)
5 499 (25.6) 112 (21.0) 232 (26.0) 155 (29.6)
≥6 102 (5.2) 12 (2.3) 40 (4.5) 50 (9.6)
Main diagnosis
Cardiovascular disease 197 (10.1) 72 (13.5) 114 (12.8) 11 (2.1)
<.001
Infectious disease 592 (30.4) 43 (8.1) 235 (26.3) 314 (60.0)
Metabolic disorder 60 (3.1) 35 (6.6) 24 (2.7) 1 (0.2)
Gastrointestinal disease 156 (8.0) 52 (9.8) 86 (9.6) 18 (3.4)
Renal disease 66 (3.4) 18 (3.4) 38 (4.3) 10 (1.9)
Cancer 360 (18.5) 89 (16.7) 174 (19.5) 97 (18.5)
Pulmonary disease 117 (6.0) 31 (5.8) 62 (6.9) 24 (4.6)
Neurological disorder 91 (4.7) 64 (12.0) 22 (2.5) 5 (1.0)
Frailty 188 (9.6) 84 (15.8) 80 (8.9) 24 (4.6)
Other 123 (6.3) 45 (8.4) 59 (6.6) 19 (3.6)
Comorbidities
Coronary heart disease 539 (27.6) 157 (29.5) 254 (28.4) 128 (24.5) .15
Congestive heart failure 341 (17.5) 86 (16.1) 180 (20.1) 75 (14.3) .01
Hypertension 1062 (54.5) 287 (53.8) 488 (54.6) 287 (54.9) .94
Cerebrovascular disease 158 (8.1) 49 (9.2) 69 (7.7) 40 (7.6) .56
Peripheral arterial disease 175 (9.0) 50 (9.4) 87 (9.7) 38 (7.3) .27
Chronic kidney disease 618 (31.7) 147 (27.6) 308 (34.5) 163 (31.2) .03
Diabetes 407 (20.9) 106 (19.9) 194 (21.7) 107 (20.5) .69
COPD 291 (14.9) 75 (14.1) 143 (16.0) 73 (14.0) .47
Dementia 72 (3.7) 24 (4.5) 31 (3.5) 17 (3.3) .50
Malignant disease 647 (33.2) 143 (26.8) 309 (34.6) 195 (37.3) <.001
Clinical findings
Barthel scale
Median (IQR) 90 (70-100) 90 (75-100) 90 (70-100) 85 (70-95) <.001
<90 Points 1143 (58.6) 268 (50.3) 542 (60.6) 333 (63.7) <.001
Admission CRP level
Median (IQR) 34.0 (8.0-110.0) 4.0 (3.0-5.3) 35.0 (18.8-62.6) 172.0 (133.0-230.0) <.001
Mean (SD) 71.8 (85.6) 4.3 (2.3) 41.9 (26.6) 191.5 (75.0) <.001
Abbreviations: BMI, bodymass index (calculated as weight in kilograms divided by
height in meters squared); COPD, chronic obstructive pulmonary disease; CRP,
C-reactive protein; IQR, interquartile range; NRS, Nutritional Risk Screening.
SI conversion factor: To convert CRP to nanomoles per liter, multiply by 9.524.
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Effect of Nutritional Support on 30-DayMortality According to Inflammation Groups
Overall, there was a significant risk reduction for 30-day mortality among patients receiving
nutritional support, with 7.0% (67 of 978) fulfilling the primary end point in the intervention group
compared with 9.7% (94 of 972) in the control group (Figure 2). This effect was also confirmed by
logistic regression analysis adjusted for sex, age, baseline nutritional risk (ie, NRS 2002 score), study
center, Barthel scale at baseline, main diagnosis, cardiovascular disease, renal disease and cancer,
with an adjusted OR of 0.61 (95% CI, 0.43-0.86; P = .005) (Table 2). To further understand whether
baseline inflammation influenced the effect of nutritional support, we investigatedmortality effects
within subgroups based on inflammation and calculated interaction statistics. The effects of
nutritional support remained robust among patients with low inflammation (adjusted OR, 0.34; 95%
CI, 0.10-1.09; P = .02) andmoderate inflammation (adjusted OR, 0.41; 95% CI, 0.24-0.68; P = .001)
(Table 2). However, among patients with high inflammatory status, there was no significant benefit
of nutritional support (adjusted OR, 1.32; 95% CI, 0.70-2.50; P = .39), with evidence for interaction
(P for interaction = .005). Figure 2 shows a time-to-event analysis regarding the primary end point
overall and stratified according to inflammation groups.
In a sensitivity analysis, we also found that when CRPwas included in themodel as a continuous
variable, therewas evidence for effectmodification for CRP on the association of nutritional support
andmortality (P for interaction = .005). We also performed a subgroup analysis limited to 592
patients (30.4%) with a systemic infection as their main admission diagnosis. Within this subgroup,
the strength of the association of nutritional support with 30-day mortality again differed among
CRP groups with adjusted ORs of 0.78 (95% CI, 0.05-13.40; P = .88) and 0.51 (95% CI, 0.17-1.53;
Figure 2. Kaplan-Meier Estimate for Time to DeathWithin 30Days According to Inflammatory Status
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P = .23) for the low andmoderate CRP groups, respectively, and an adjusted OR of 1.24 (95%CI, 0.51-
3.00; P = .64) for the high CRP group.
Effect of Nutritional Support on SecondaryOutcomes According
to Inflammation Groups
We also conducted several analyses to investigate the association of nutritional support with
different secondary short-term outcomesmeasured at 30 days and long-term outcomesmeasured
at 180 days (Table 2). For 180-day mortality and major complications, patients with high
inflammation on admission tended to benefit less from nutritional support (180-dmortality: adjusted
OR, 0.95; 95% CI, 0.58-1.55; P = .82; major complications: adjusted OR, 1.19; 95% CI, 0.59-2.38;
P = .63), but these results were not significant in the interaction analysis. For other secondary end
points, results remained robust with no evidence of interaction due to baseline inflammation status.
Association of Nutritional SupportWith CRPKinetics
Finally, we investigated whether nutritional support was associated with CRP kinetics during the first
7 days of inpatient treatment. As shown in Figure 3, CRP levels increased from baseline to day 2 and
thereafter decreased stepwisewith no difference between patients in the intervention group and the
control group at any day. Themean (SD) CRP levels for the control and intervention groups on day 1
were 70.93 (2.72) mg/L and 72.61 (2.77) mg/L, respectively. On day 2, these increased to 101.08
(7.72) mg/L and 98.48 (7.80) mg/L, respectively, before decreasing to 45.76 (2.74) mg/L and 50.66
(3.09) mg/L, respectively, on day 7.
Discussion
The key findings of this secondary analysis investigating the effect of nutritional support among
hospitalized patients according to their baseline inflammatory status are 2-fold. First, we found that
patients with high baseline inflammation (ie, CRP levels >100 mg/L) were not associated with a
benefit from nutritional support with regard to 30-daymortality (ie, the primary end point of this
analysis), with a significant result in interaction analysis. Patients with low andmoderate
inflammation were associated with a significant reduction in 30-daymortality, similar to the overall
population. These results remained similar in a subgroup analysis limited to patients with a systemic
infection as main admission diagnosis, suggesting that inflammation rather than infection was the
main driver of results. Second, we did not find that nutritional support was associated with
Figure 3. C-Reactive Protein (CRP) KineticsWithin the First 7 Days of Inpatient Treatment According
to Randomization Group
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inflammation as mirrored by a similar kinetic profile of CRP levels over the first 7 days of inpatient
treatment among individuals with and without nutritional support.
Recently, there have been several studies showing that nutritional support has a positive effect
on clinical outcomes among patients withmalnourishment, particularly amongmedical patients with
multiple illnesses and comorbidities.4,15,16 Nevertheless, because trials in some populations have
reported negative results, it has been hypothesized that not all patients would have the same
response to nutrition, emphasizing the concept of personalized nutrition.17-19 Inflammation could be
a key factor, which could explain these differences.20 In fact, there is a strong biological explanation
for why inflammation is associated with the effect of nutritional support on patient outcomes.
Previous studies have found that inflammation because of acute or chronic disease causes metabolic
changes by influencing different pathways.21,22 Inflammation has effects on appetite and food
intake, gastrointestinal functioning of the stomach and gut, and, on a cellular level, on insulin
resistance, among others.23 Among other mechanisms, these effects are mediated by circulating
cytokines released as part of the systemic inflammatory response.24 Their stress-response release
during illness plays an integral role in the systemic inflammatory response, and several studies have
found cytokines to be associated with disease-related anorexia, weight loss, decline in cognitive
function, frailty, and anemia. For example, interleukin-6 and tumor necrosis factor-α interact with
brain circuitries that control food intake, delayed gastric emptying, andmuscle catabolism.25
Interestingly, the cytokine-induced downregulation of food intake during acute illness may also have
a beneficial biological role, given that high intake of nutrition during severest illness (ie, overfeeding)
has been shown to reduce autophagy, a mechanism important for cell detoxication during
illness.26-28 These observations have also been confirmed in several clinical trials that report no
benefit from full-replacement feeding among patients who are critically ill.29,30 The findings of our
study, which looked at a lower-risk patient population in medical wards, are in line with these
observations. Overall, they demonstrate that patients do benefit from nutritional support, but those
with initially very high levels of CRP and thus marked inflammation may not respond. Of note, our
subgroup analysis limited to patients with systemic infection also suggests that it is inflammation and
not infection that is driving these results. Individualized nutritional support in these cases even tends
to have a harmful effect on 30-day mortality. This finding would also be in line with data observed
in patients who are critically ill, who typically have a very strong systemic inflammatory response.
Thus, our findings support the concept of individualized nutritional support based on a patient’s
initial presentation andmarkers of inflammation, possibly with lower targets for those patients with
higher baseline levels of inflammation. However, this hypothesis needs confirmation in
prospective trials.
We also investigated whether the association of inflammation and nutrition was bidirectional,
ie, whether nutritional support would also be associated with inflammation mirrored by the kinetics
of CRP levels over time. However, there was no difference in inflammation during the first 7 days of
inpatient treatment for those with and without nutritional support. Thus, there is no evidence from
our analysis that the modulation of inflammation through nutritional support in acute situations
would be responsible for the positive effects seen on outcomes in previous trials. It is still possible
that nutrition has beneficial effects in chronic situations, eg, by modulation of low-grade
inflammation. Future trials should look at this particular question to better understand the
physiopathology regarding the effects of nutrition on outcome.
Strengths and Limitations
To our knowledge, this is the first large-scale analysis to investigate whether inflammation is
associated with response to nutritional support based on a secondary analysis of a randomized
clinical trial. However, we are aware of several limitations. First, we only measured CRP levels and did
not look at other cytokines, which could have deliveredmore detailed information. Second, the
sample size may have been too small to find significant interactions in some of the outcomes
investigated. Third, we did not adjust our analysis for all possible confounders; therefore, there could
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still be a residual confounding of our analysis. Fourth, because it is a secondary analysis, our results
are hypothesis generating rather than definite and require validation in an independent sample.
Conclusions
Based on this secondary analysis of a multicenter randomized clinical trial, patients’ inflammatory
status at admission was associated with their response to nutritional support. These findings may
help to better individualize nutritional support based on patients’ initial presentation andmarkers of
inflammation.
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